Haemonetics Co. (NYSE:HAE) Shares Sold by Raymond James & Associates

Raymond James & Associates trimmed its stake in shares of Haemonetics Co. (NYSE:HAE) by 26.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,050 shares of the medical instruments supplier’s stock after selling 8,751 shares during the quarter. Raymond James & Associates’ holdings in Haemonetics were worth $2,057,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Haemonetics during the 4th quarter worth about $345,000. Contravisory Investment Management Inc. lifted its holdings in shares of Haemonetics by 7.4% in the 4th quarter. Contravisory Investment Management Inc. now owns 3,507 shares of the medical instruments supplier’s stock valued at $300,000 after purchasing an additional 242 shares during the last quarter. Riverwater Partners LLC lifted its holdings in shares of Haemonetics by 1.5% in the 4th quarter. Riverwater Partners LLC now owns 15,784 shares of the medical instruments supplier’s stock valued at $1,350,000 after purchasing an additional 231 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock valued at $482,017,000 after purchasing an additional 27,146 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Haemonetics by 28.7% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 37,344 shares of the medical instruments supplier’s stock valued at $3,345,000 after purchasing an additional 8,318 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Performance

NYSE HAE opened at $84.21 on Wednesday. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The business’s 50 day moving average is $78.56 and its two-hundred day moving average is $82.76. Haemonetics Co. has a 12-month low of $70.74 and a 12-month high of $95.26. The stock has a market capitalization of $4.28 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 2.01 and a beta of 0.36.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same quarter in the previous year, the firm posted $0.85 EPS. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. Research analysts expect that Haemonetics Co. will post 3.95 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Barrington Research reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.